Navigation Links
Positive Phase III Top Line Results Demonstrate Efficacy of NER1006, a Novel, Low Volume Bowel Preparation, vs. Trisulfate
Date:10/8/2015

LONDON, October 9, 2015 /PRNewswire/ --

Norgine today announced positive top line results for its phase III study, NOCT, a multicentre, randomised, parallel-group clinical trial comparing the bowel cleansing efficacy of a two-day split-dosing regimen of NER1006, versus a split-dosing regimen of a trisulfate bowel cleansing solution (SUPREP®) in adult patients undergoing screening, surveillance or diagnostic colonoscopy. The NOCT study also assessed the compliance, safety, patient acceptability and tolerability of NER1006.

     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a)

The NOCT study, which enrolled 621 patients, met both of its primary endpoints.

Peter Martin, Norgine's Chief Operating Officer, said; "These positive top-line results demonstrate the potential of NER1006 as a novel bowel cleansing agent to deliver an effective colonoscopy. These data are encouraging as a major milestone on the development of this novel bowel cleansing agent".

The NOCT study is part of Norgine's NER1006 Phase III clinical trials programme. The programme includes two additional multicentre, randomised, parallel-group clinical trials, MORA and DAYB, that are expected to report in 2015.

Full evaluation of the data is ongoing. Complete results from the NOCT study will be submitted to a scientific meeting in 2016. NER1006 is not approved for use.

Notes to Editors: 

About NER1006 

NER1006 is a novel, low volume polyethylene glycol based bowel preparation that has been developed to provide whole bowel cleansing, with an additional focus on the ascending colon. This low volume solution is developed not only to support improved patient acceptability and compliance but also to contribute to effectiveness of colonoscopy procedures at detecting colon cancer and for optimised bowel surveillance, through effective bowel cleansing.

About Norgine 

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2014, Norgine's total revenue was €296 million and the company employs over 1,000 people.

Norgine provides expertise and 'know how' in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine's approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales, and one in Dreux, France.

For more information, please visit http://www.norgine.com

In 2012, Norgine established a complementary business, Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit http://www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

GL/COR/1015/0049. October 2015

Media Contacts:
Isabelle Jouin, T: +44(0)1895-453643
Charlotte Andrews, T: +44(0)1895-453607
Follow us @norgine


'/>"/>
SOURCE Norgine B.V.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. SynAgile Corporation Announces Positive Phase 2a Results for Continuous, Noninvasive, Intraoral Levodopa-Carbidopa Administration to Treat Parkinsons Disease
2. Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
3. QT Vascular Announces Positive Outcome in Spectranetics/AngioScore Patent Trial
4. Regen BioPharma, Inc. Announces Positive Results from GLP Safety Study for HemaXellerate
5. Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe
6. Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide
7. Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study
8. BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ
9. Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial
10. Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome
11. Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2018)... ... 13, 2018 , ... Anxiety is the most common mental ... Thomas and BJ Goodson, anxiety-relieving wearable company The TouchPoint Solution, and the Phoenix ... stigma surrounding anxiety. Currently less than 40% receive treatment. Anxiety affects everyone differently ...
(Date:12/13/2018)... Calif. (PRWEB) , ... December 13, 2018 , ... ... for Accessibility grant from Microsoft to help further our efforts in improving ... the familiar technology of mobile devices in combination with power of artificial intelligence ...
(Date:12/10/2018)... SARASOTA, Fla. (PRWEB) , ... December 10, 2018 ... ... (“BayView Dental”) are pleased to announce the formation of Parkview Dental Partners (“Parkview ... by CEO, Dr. Kenneth Liszewski, founder of BayView Dental, a group dental practice ...
Breaking Medicine Technology:
(Date:12/18/2018)... ... , ... The Boston Center for Facial Rejuvenation is proud to announce that ... Doctors for 2018. This annual list, put out by healthcare advocate Castle Connolly, spotlights ... to the top tier of Castle Connolly’s rankings. , Established in 1991, the ...
(Date:12/18/2018)... ... December 18, 2018 , ... The sacroiliac (SI) joint ... is estimated that SI joint pain affects 15-25% of patients suffering from LBP. A ... had previously undergone lumbar fusion surgery and pregnancy related pelvic instability is a common ...
(Date:12/16/2018)... ... ... Solo Printing, a Miami-based commercial printing company, is giving back to the community with ... with access to clean water and sanitation. , BLUE Missions cultivates water ... of life in rural communities. The non-profit believes water is the foundation of a ...
(Date:12/14/2018)... , ... December 14, 2018 , ... ... HospitalPriceIndex.com, a patient-friendly, online tool that provides a strategic and meaningful way to ... January 1, 2019, CMS will require all hospitals to make public a list ...
(Date:12/14/2018)... ... ... To help change the way people sit, an experienced Australian chiropractor, David France, ... that creates the perfect angle between the legs and back to reduce back pain ... on November 13th, 2018, and has raised more than $125,000 USD to break the ...
Breaking Medicine News(10 mins):